Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET
Company Participants
Sherry Aulin - CFO
Ian Mortimer - President and CEO
Chris Kenney - CMO
Chris Von Seggern - CCO
Conference Call Participants
Brian Abrahams - RBC Capital Markets
Tessa Romero - JPMorgan
Paul Choi - Goldman Sachs
Joseph Thome - TD Cowen
Andrew Tsai - Jefferies
Rudy Li - SVB Securities
Laura Chico - Wedbush
Rohit Bhasin - Needham & Company
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2022 Xenon Pharmaceuticals, Inc. Earnings Conference Call.
I would now like to turn the call over to Sherry Aulin, CFO. Please go ahead.
Sherry Aulin
Good afternoon. Thank you for joining us on our call and webcast to discuss Xenon's fourth quarter and full year 2022 financial and operating results. Joining me are Ian Mortimer, Xenon's President and Chief Executive Officer; Dr. Chris Kenney, Xenon's Chief Medical Officer; and Dr. Chris Von Seggern, Xenon's Chief Commercial Officer.
Ian will open today's call with a summary of progress across our pipeline. Chris Kenny will provide an overview of our XEN1101 Phase 3 epilepsy program, as well as a brief summary of additional supporting X-TOLE data we released in December, and I will summarize our financial results, progress within our partnered programs, and our anticipated company milestone events. Chris Von Seggern will be available during our Q&A session to address questions about our commercialization strategies.
Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the timing of and potential results from clinical trials; the potential efficacy, safety profile, future development plans, addressable market, regulatory success, and commercial potential of our and our partners' product candidates; the efficacy of our clinical trial designs; our ability to successfully develop and achieve milestones in our XEN1101 and other development programs; the timing and results of our interactions with regulators; our ability to successfully develop and obtain regulatory approval of XEN1101 and our other product candidates, anticipated enrollment in our clinical trials, and the timing thereof; and our expectation that we will have sufficient cash to fund operations into 2026.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time-to-time in our SEC filings. Our results may differ materially from those projected on today's call. We undertake no obligation to publicly update any forward-looking statement.